CJC-1295 (without DAC) vs CJC-1295 with DAC
Well Studied vs Well Studied
avoid Researched · 95% Choose one variant based on desired release kinetics.
Molecular Data
CJC-1295 (without DAC) CJC-1295 with DAC
Weight 3,367.97 Da 3,647.28 Da
Half-life 30 minutes - 2 hours 6-8 days
Chain 30 amino acids 30 amino acids
Type GHRH analog GHRH analog with DAC
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
CJC-1295 (without DAC) CJC-1295 with DAC
Status Well Studied Well Studied
References 5 studies 4 studies
Latest November 2024 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.